You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Toll-like receptor agonists: a patent review (2011 – 2013)
|
|---|---|
| Published in |
Expert Opinion on Therapeutic Patents, January 2014
|
| DOI | 10.1517/13543776.2014.880691 |
| Pubmed ID | |
| Authors |
Waleed M Hussein, Tzu-Yu Liu, Mariusz Skwarczynski, Istvan Toth |
| Abstract |
Toll-like receptors (TLRs) are a crucial part of the innate immunity and present the first line of defense against pathogens. In humans, there are ten TLRs, with TLR3, 7, 8 and 9 located in intracellular vesicles and the remaining expressed on the cell surface. These transmembrane protein receptors recognize a wide range of pathogen components. A large number of TLR agonists, either derived from pathogen components or modified synthetic molecules, were developed and investigated for their ability to stimulate an immune response. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Colombia | 1 | 1% |
| Germany | 1 | 1% |
| Korea, Republic of | 1 | 1% |
| United Kingdom | 1 | 1% |
| Canada | 1 | 1% |
| Unknown | 69 | 93% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 18 | 24% |
| Student > Ph. D. Student | 14 | 19% |
| Student > Bachelor | 7 | 9% |
| Student > Doctoral Student | 7 | 9% |
| Student > Master | 5 | 7% |
| Other | 12 | 16% |
| Unknown | 11 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 19 | 26% |
| Biochemistry, Genetics and Molecular Biology | 11 | 15% |
| Medicine and Dentistry | 10 | 14% |
| Chemistry | 8 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 5% |
| Other | 11 | 15% |
| Unknown | 11 | 15% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 August 2022.
All research outputs
#2,527,136
of 23,577,654 outputs
Outputs from Expert Opinion on Therapeutic Patents
#56
of 1,316 outputs
Outputs of similar age
#30,861
of 309,882 outputs
Outputs of similar age from Expert Opinion on Therapeutic Patents
#3
of 20 outputs
Altmetric has tracked 23,577,654 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,316 research outputs from this source. They receive a mean Attention Score of 4.9. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 309,882 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 20 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.